Perspective Therapeutics Q1 net loss $18.2M; VMT-α-NET cohort enrollment reaches 40 patients

Perspective Therapeutics, Inc.

2025-Q1 EPS reported -$0.25

Net loss $18.2M ($0.25 loss per share) vs $12.3M loss in prior year; R&D spend +92% to $14.3M.
Cash $212M as of March 31; expects funding into late 2026; sold $10.2M in ATM shares in Feb 2025 at ~$3.02/share.
VMT-α-NET: 40 patients enrolled in Cohort 2 as of April 30; data accepted for oral ASCO 2025 presentation.
VMT01: first patient treated at new monotherapy dose level (April 2025) and in combo with nivolumab (March 2025).
PSV359: first patient dosed; three new U.S. manufacturing sites underway for future commercial demand.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.